CorMedix's consistent loss per share year-over-year suggests stability in the company's financial performance. However, since there is no improvement in reducing losses, the impact on the stock price is likely to be neutral in the short term. Investors may have anticipated these results, and without a positive or negative surprise, significant stock movement is not expected.